Studying Platelet Cell Types in People With Sickle Cell Disease
Looks at bone marrow and blood cell types in adults with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Megakaryocyte Heterogeneity in Sickle Cell Disease
Key facts
- Where
- Pointe-à-Pitre, GuadeloupeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sickle cell disease type SS or SC who are stable and followed at the sickle cell center of Guadeloupe. A control group of adults without chronic disease having hip or knee replacement can also join.
- Age
- Older than 18 years
- Sex
- All
- Disease stage
- Sickle cell disease type SS or SC, confirmed by electrophoresis or HPLC. Clinically stable: no complication in the last month.
- Earlier treatment
- No transfusion in the last three months.
Main reasons for not taking part
- Younger than 18 years
- Hemoglobinopathy other than SS and SC sickle cell disease
- On transfusion therapy or bleeding therapy for less than three months
- Not affiliated to national social security
- Pregnant or breastfeeding
Read by machine on 9 November 2026.
Where in Guadeloupe
- CHU de la GuadeloupePointe-à-Pitre, GuadeloupeContact: Valérie Hamony SoterNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de la Guadeloupe
- Trial code
- NCT06850337
- Record updated
- 25 May 2025
- Original description
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.Read full original descriptionShow less
Characterization of Megakaryocytic Subpopulations and the "Immune" Phenotype of Platelets of the Sickle Cell Disease Patient
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.
The main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the "immune" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.
Inclusion: patients with SS or SC SCD; diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies; patients older than 18 years at inclusion; clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months); patient followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre); patients who will provide written informed consent in accordance with the Declaration of Helsinki; patients affiliated to national social security; the control group (AA subjects) will be patients older than 18 years old who come at the University hospital of Guadeloupe, (Pointe à Pitre) for hip or knee replacement and will do not suffer from chronic disease.
Exclusion: patients with a transfusion therapy or on bleeding therapy for less than three months; patients younger than 18 years old; patients with hemoglobinopathy other than SS and SC SCD; patients no affiliated to national social security; pregnant or breastfeeding patients.